Beneficial effects of statins on perioperative cardiovascular outcome

Current Opinion in Anaesthesiology

Volumn 19, Issue 4, 2006, Pages 418-422

  Dunkelgrun, Martin ^a   Schouten, Olaf ^a   Feringa, Harm H ^a   Vidakovic, Radosav ^a   Poldermans, Don ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular complications; Perioperative; Pleiotropy; Statins; Vulnerable plaques

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE KIDNEY FAILURE; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CAROTID ENDARTERECTOMY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; INTRACARDIAC THROMBOSIS; MYOPATHY; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; PLEIOTROPY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; STROKE; SURGICAL RISK; UNSTABLE ANGINA PECTORIS;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL INFARCTION; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME;

EID: 33745886524     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aco.0000236142.53969.7e     Document Type: Review

References (68)

1. Scandinavian Simvastatine Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-1307.
3. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-1357.
4. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615-1622.
5. Shepherd L, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002; 360:1623-1630.
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360:7-22.
7. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Anti-hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288:2998-3007.
8. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a Multicenter randomized controlled trial. Lancet 2003; 361:1149-1158.
9. Liao JK. Clinical implications for statin pleiotropy. Curr Opin Lipidol 2005; 16:624-629. This is an excellent review of all the different pleiotropic effects of statins and their possible clinical implications.
10. Arnaud C, Veillard NR, March F, et al. Cholesterol-independent effects of statins in inflammation, immunomodulation and atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5:127-134.
11. Cohen MC, Aretz TH. Histological analysis of coronary artery lesions in fatal postoperative myocardial infarction. Cardiovasc Pathol 1999; 8:133-139.
12. Landesberg G. The pathophysiology of perioperative myocardial infarction: facts and perspectives. J Cardiothorac Vasc Anesth 2003; 17:90-100.
13. Dawood MM, Gupta DK, Southern J, et al. Pathology of fatal perioperative myocardial infarction: implications regarding pathophysiology and prevention. Int J Cardiol 1996; 57:37-44.
14. Priebe HJ. Perioperative myocardial infarction: aetiology and prevention. Br J Anaesth 2005; 95:3-19. This is a comprehensive current review of the different mechanisms that lead to perioperative myocardial infarction.
15. Fuster V, Moreno PR, Fayad ZA, et al. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol 2005; 46:937-954.
16. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92:657-671.
17. Klein LW. Clinical implications and mechanisms of plaque rupture in the acute coronary syndromes. Am Heart Hosp J 2005; 3:249-255. This is a review of pathophysiology of coronary atherosclerosis development and plaque rupture, and possible mechanisms of plaque stabilization.
18. Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103:926-933.
19. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003; 108:1664-7162.
20. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 2003; 108:1772-1778.
21. Yeh ET. High-sensitivity C-reactive protein as a risk assessment tool for cardiovascular disease. Clin Cardiol 2005; 28:408-412.
22. Koenig W. Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein. Int J Cardiol 2005; 98:199-206.
23. Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 2005; 46:1425-1433.
24. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95:1126-1131.
25. Vasa M, Fichtischerer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001; 103:2885-2890.
26. Fitzgerald DJ, Roy L, Catella F, et al. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315:983-989.
27. Yamakuchi M, Greer JJ, Cameron SJ, et al. HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size. Circ Res 2005; 96:1185-1192.
28. Furman C, Copin C, Kandoussi M, et al. Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability. Atherosclerosis 2004; 174:93-98.
29. Dichtl W, Dulak J, Frick M, et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003; 23:58-63.
30. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352:29-38.
31. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425-1435.
32. Halcox JP, Deanfield JE. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 2004; 109:1142-1148.
33. Ky B, Rader DJ. The effects of statin therapy on plasma markers of inflammation in patients without vascular disease. Clin Cardiol 2005; 28:67-70.
34. Yeh ET. High-sensitivity C-reactive protein as a risk assessment tool for cardiovascular disease. Clin Cardiol 2005; 28:408-412. This review describes the biological properties of C-reactive protein.
35. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res 2005; 97:1232-1235.
36. Wright DG, Lefer DJ. Statin mediated protection of the ischemic myocardium. Vascul Pharmacol 2005; 42:265-270.
37. Ridker PM. C-reactive protein, inflammation, and cardiovascular disease: clinical update. Tex Heart Inst J 2005; 32:384-386.
38. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005; 4:977-987.
39. Schoenbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004; 109:II18-II26.
40. Mason RP, Walter MF, Day CA, et al. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol 2005; 96:F11-F23.
41. Robinson JG, Smith B, Maheshwari N, et al. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005; 46:1855-1862.
42. Fenton JW 2nd, Brezniak DV, Ofosu FA, et al. Statins and thrombin. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5:115-120.
43. Sanguigni V, Pignatelli P, Lenti L, et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 2005; 111:412-419.
44. Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111:2356-2363. This recent study showed that ezetimibe and simvastatin have different effects on endothelial function, despite similar effects on cholesterol levels.
45. Karatzis E, Lekakis J, Papamichael C, et al. Rapid effect of pravastatin on endothelial function and lipid peroxidation in unstable angina. Int J Cardiol 2005; 101:65-70. In this study, endothelial function improved within 10 days of statin therapy, which occurred before any significant reduction in blood lipids, showing an early pleiotropic effect.
46. Azar RR, Badaoui G, Sarkis A, et al. Effects of tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6, and soluble CD40 ligand following percutaneous coronary interventions in patients with stable coronary artery disease. Am J Cardiol 2005; 95:236-240.
47. Durazzo AE, Machado FS, Ikeoka DT, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg 2004; 39:967-975; discussion 975-976.
48. Poldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 2003; 107:1848-1851.
49. Landesberg G, Mosseri M, Wolf YG, et al. Preoperative thallium scanning, selective coronary revascularization, and long-term survival after major vascular surgery. Circulation 2003; 108:177-183.
50. Kertai MD, Boersma E, Westerhout CM, et al. Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. Am J Med 2004; 116:96-103.
51. Kertai MD, Boersma E, Westerhout CM, et al. A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery. Eur J Vasc Endovasc Surg 2004; 28:343-352.
52. Lindenauer PK, Pekow P, Wang K, et al. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 2004; 291: 2092-2099.
53. Dotani MI, Elnicki DM, Jain AC, et al. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol 2000; 86:1128-1130.
54. Pan W, Pintar T, Anton J, et al. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation 2004; 110:1145-1149.
55. O'Neil-Callahan K, Katsimaglis G, Tepper MR, et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the Statins for Risk Reduction in Surgery (StaRRS) study. J Am Coll Cardiol 2005; 45:336-342. This large, retrospective study, investigated the effects of statin use on perioperative complications in patients undergoing vascular surgery.
56. Kennedy J, Quan H, Buchan AM, et al. Statins are associated with better outcomes after carotid endarterectomy in symptomatic patients. Stroke 2005; 36:2072-2076. In this large, multicenter study the cardioprotective effects of statins in patients undergoing carotid endarterectomy was studied.
57. McGirt MJ, Perler BA, Brooke BS, et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors reduce the risk of perioperative stroke and mortality after carotid endarterectomy. J Vasc Surg 2005; 42:829-836. This study investigated the effects of statins on the perioperative outcome in patients undergoing carotid endarterectomy, with or without coronary artery bypass grafting.
58. Biccard BM, Sear JW, Foex P. Statin therapy: a potentially useful perioperative intervention in patients with cardiovascular disease. Anaesthesia 2005; 60:1106-1114. This is a current and up-to-date review on the different studies on perioperative cardiovascular outcome and statin therapy, including recommendations for timing and duration of administration, therapeutic targets, safety and cost-effectiveness.
59. Ballista S, Paulette R, Cosine A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109:11150-11157.
60. Owczarek J, Jasinska M, Orszulak-Michalak D. Drug-induced myopathies: An overview of the possible mechanisms. Pharmacol Rep 2005; 57:23-34. This review focuses on pathophysiological methods of muscular injuries induced by statins, fibrates, as well as other agents.
61. Waters DD. Safety of high-dose atorvastatin therapy. Am J Cardiol 2005; 96:F69-F75.
62. Wortmann RL, Tipping RW, Levine JG, et al. Frequency of myopathy in patients receiving lovastatin. Am J Cardiol 2005; 95:983-985.
63. Hansen KE, Hildebrand JP, Ferguson EE, et al. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005; 165:2671-2676.
64. Wilhelmi M, Winterhalter M, Fischer S, et al. Massive postoperative rhabdomyolysis following combined CABG/abdominal aortic replacement: a possible association with HMG-CoA reductase inhibitors. Cardiovasc Drugs Ther 2002; 16:471-475.
65. Forestier F, Breton Y, Bonnet E, Janvier G. Severe rhabdomyolysis after laparoscopic surgery for adenocarcinoma of the rectum in two patients treated with statins. Anesthesiology 2002; 97:1019-1021.
66. Tong J, Laport G, Lowsky R. Rhabdomyolysis after concomitant use of cyclosporine and simvastatin in a patient transplanted for multiple myeloma. Bone Marrow Transplant 2005; 36:739-740.
67. Schouten O, Kertai MD, Bax JJ, et al. Safety of perioperative statin use in high-risk patients undergoing major vascular surgery. Am J Cardiol 2005; 95:658-660. This study examined the effect of short and long-term statin use on the perioperative cardiovascular complications after vascular surgery.
68. Schouten O, Poldermans D, Visser L, et al. Fluvastatin and bisoprolol for the reduction of perioperative cardiac mortality and morbidity in high-risk patients undergoing noncardiac surgery: rationale and design of the DECREASE-IV study. Am Heart J 2004; 148:1047-1052.